Skip to main content
Top
Published in: BMC Health Services Research 1/2015

Open Access 01-06-2015 | Research article

Is the choice of the statistical model relevant in the cost estimation of patients with chronic diseases? An empirical approach by the Piedmont Diabetes Registry

Authors: Eva Pagano, Alessio Petrelli, Roberta Picariello, Franco Merletti, Roberto Gnavi, Graziella Bruno

Published in: BMC Health Services Research | Issue 1/2015

Login to get access

Abstract

Background

Chronic diseases impose large economic burdens. Cost analysis is not straightforward, particularly when the goal is to relate costs to specific patterns of covariates, and to compare costs between diseased and healthy populations. Using different statistical methods this study describes the impact on results and conclusions of analyzing health care costs in a population with diabetes.

Methods

Direct health care costs of people living in Turin were estimated from administrative databases of the Regional Health System. Patients with diabetes were identified through the Piedmont Diabetes Registry. The effect of diabetes on mean annual expenditure was analyzed using the following multivariable models: 1) an ordinary least squares regression (OLS); 2) a lognormal linear regression model; 3) a generalized linear model (GLM) with gamma distribution. Presence of zero cost observation was handled by means of a two part model.

Results

The OLS provides the effect of covariates in terms of absolute additive costs due to the presence of diabetes (€ 1,832). Lognormal and GLM provide relative estimates of the effect: the cost for diabetes would be six fold that for non diabetes patients calculated with the lognormal. The same data give a 2.6-fold increase if calculated with the GLM. Different methods provide quite different estimated costs for patients with and without diabetes, and different costs ratios between them, ranging from 3.2 to 5.6.

Conclusions

Costs estimates of a chronic disease vary considerably depending on the statistical method employed; therefore a careful choice of methods to analyze data is required before inferring results.
Literature
2.
go back to reference Muka T, Imo D, Jaspers L, Colpani V, Chaker L, van der Lee SJ, et al. The global impact of non-communicable diseases on healthcare spending and national income: a systematic review. Eur J Epidemiol. 2015;30:251–77.PubMedCrossRef Muka T, Imo D, Jaspers L, Colpani V, Chaker L, van der Lee SJ, et al. The global impact of non-communicable diseases on healthcare spending and national income: a systematic review. Eur J Epidemiol. 2015;30:251–77.PubMedCrossRef
3.
go back to reference Gregori D, Petrinco M, Bo S, Desideri A, Merletti F, Pagano E. Regression models for analyzing costs and their determinants in health care: an introductory review. Int J Qual Health Care. 2011;23:331–41.PubMedCrossRef Gregori D, Petrinco M, Bo S, Desideri A, Merletti F, Pagano E. Regression models for analyzing costs and their determinants in health care: an introductory review. Int J Qual Health Care. 2011;23:331–41.PubMedCrossRef
4.
go back to reference Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Analysing Costs. Applied Methods fo Cost-effectiveness Analysis in Health Care. Oxford: Oxford University Press; 2011. Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Analysing Costs. Applied Methods fo Cost-effectiveness Analysis in Health Care. Oxford: Oxford University Press; 2011.
5.
go back to reference Duan N, Manning WG, Morris CN, Newhouse JP. A comparison of alternative models for the demand for medical care. J Bus Econ Stat. 1983;1:115–26. Duan N, Manning WG, Morris CN, Newhouse JP. A comparison of alternative models for the demand for medical care. J Bus Econ Stat. 1983;1:115–26.
6.
7.
go back to reference Basu A, Manning WG. Estimating lifetime or episode-of-illness costs under censoring. Health Econ. 2010;19:1010–28.PubMedCrossRef Basu A, Manning WG. Estimating lifetime or episode-of-illness costs under censoring. Health Econ. 2010;19:1010–28.PubMedCrossRef
8.
go back to reference Young TA. Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics. 2005;23:1229–42.PubMedCrossRef Young TA. Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics. 2005;23:1229–42.PubMedCrossRef
9.
go back to reference Grieve R, Nixon R, Thompson SG, Normand C. Using multilevel models for assessing the variability of multinational resource use and cost data. Health Econ. 2005;14:185–96.PubMedCrossRef Grieve R, Nixon R, Thompson SG, Normand C. Using multilevel models for assessing the variability of multinational resource use and cost data. Health Econ. 2005;14:185–96.PubMedCrossRef
10.
go back to reference Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Econ. 2005;14:471–85.PubMedCrossRef Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Econ. 2005;14:471–85.PubMedCrossRef
11.
go back to reference Nixon RM, Thompson SG. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. Health Econ. 2005;14:1217–29.PubMedCrossRef Nixon RM, Thompson SG. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. Health Econ. 2005;14:1217–29.PubMedCrossRef
13.
go back to reference Mihaylova B, Briggs A, O’Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20:897–916.PubMedPubMedCentralCrossRef Mihaylova B, Briggs A, O’Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20:897–916.PubMedPubMedCentralCrossRef
14.
go back to reference Bruno G, Picariello R, Petrelli A, Panero F, Costa G, Cavallo-Perin P, et al. Direct costs in diabetic and non diabetic people: the population-based Turin study, Italy. Nutr Metab Cardiovasc Dis. 2012;22:684–90.PubMedCrossRef Bruno G, Picariello R, Petrelli A, Panero F, Costa G, Cavallo-Perin P, et al. Direct costs in diabetic and non diabetic people: the population-based Turin study, Italy. Nutr Metab Cardiovasc Dis. 2012;22:684–90.PubMedCrossRef
15.
go back to reference Gnavi R, Karaghiosoff L, Costa G, Merletti F, Bruno G. Socio-economic differences in the prevalence of diabetes in Italy: the population-based Turin study. Nutr Metab Cardiovasc Dis. 2008;18:678–82.PubMedCrossRef Gnavi R, Karaghiosoff L, Costa G, Merletti F, Bruno G. Socio-economic differences in the prevalence of diabetes in Italy: the population-based Turin study. Nutr Metab Cardiovasc Dis. 2008;18:678–82.PubMedCrossRef
16.
go back to reference Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17:283–95.PubMedCrossRef Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17:283–95.PubMedCrossRef
17.
go back to reference Duan N. Smearing estimate: a non parametric retransformation method. J Am Stat Assoc. 1983;78:605–10.CrossRef Duan N. Smearing estimate: a non parametric retransformation method. J Am Stat Assoc. 1983;78:605–10.CrossRef
18.
19.
go back to reference Madsen H, Thyregod P. Introduction to General and Generalized Linear Models: CRC Press. 2010. Madsen H, Thyregod P. Introduction to General and Generalized Linear Models: CRC Press. 2010.
20.
go back to reference Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Annu Rev Public Health. 1999;20:125–44.PubMedCrossRef Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Annu Rev Public Health. 1999;20:125–44.PubMedCrossRef
21.
go back to reference Cole SR. Simple bootstrap statistical inference using the SAS system. Comput Methods Programs Biomed. 1999;60:79–82.PubMedCrossRef Cole SR. Simple bootstrap statistical inference using the SAS system. Comput Methods Programs Biomed. 1999;60:79–82.PubMedCrossRef
22.
go back to reference Palmer AJ, Mount Hood 5 Modeling G, Clarke P, Gray A, Leal J, Lloyd A, et al. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health. 2013;16:670–85.PubMedCrossRef Palmer AJ, Mount Hood 5 Modeling G, Clarke P, Gray A, Leal J, Lloyd A, et al. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health. 2013;16:670–85.PubMedCrossRef
23.
go back to reference Baumeister SE, Boger CA, Kramer BK, Doring A, Eheberg D, Fischer B, et al. Effect of chronic kidney disease and comorbid conditions on health care costs: A 10-year observational study in a general population. Am J Nephrol. 2010;31:222–9.PubMedCrossRef Baumeister SE, Boger CA, Kramer BK, Doring A, Eheberg D, Fischer B, et al. Effect of chronic kidney disease and comorbid conditions on health care costs: A 10-year observational study in a general population. Am J Nephrol. 2010;31:222–9.PubMedCrossRef
24.
go back to reference Icks A, Claessen H, Strassburger K, Tepel M, Waldeyer R, Chernyak N, et al. Drug costs in prediabetes and undetected diabetes compared with diagnosed diabetes and normal glucose tolerance: results from the population-based KORA Survey in Germany. Diabetes Care. 2013;36:e53–4.PubMedPubMedCentralCrossRef Icks A, Claessen H, Strassburger K, Tepel M, Waldeyer R, Chernyak N, et al. Drug costs in prediabetes and undetected diabetes compared with diagnosed diabetes and normal glucose tolerance: results from the population-based KORA Survey in Germany. Diabetes Care. 2013;36:e53–4.PubMedPubMedCentralCrossRef
25.
go back to reference Li R, Bilik D, Brown MB, Zhang P, Ettner SL, Ackermann RT, et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care. 2013;19:421–30.PubMedPubMedCentral Li R, Bilik D, Brown MB, Zhang P, Ettner SL, Ackermann RT, et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care. 2013;19:421–30.PubMedPubMedCentral
26.
go back to reference Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, et al. Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes mellitus. Diabetes Care. 2013. Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, et al. Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes mellitus. Diabetes Care. 2013.
27.
go back to reference Egede LE, Gebregziabher M, Dismuke CE, Lynch CP, Axon RN, Zhao Y, et al. Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care. 2012;35:2533–9.PubMedPubMedCentralCrossRef Egede LE, Gebregziabher M, Dismuke CE, Lynch CP, Axon RN, Zhao Y, et al. Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care. 2012;35:2533–9.PubMedPubMedCentralCrossRef
28.
go back to reference Kilian R, Matschinger H, Loeffler W, Roick C, Angermeyer MC. A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment. J Ment Health Policy Econ. 2002;5:21–31.PubMed Kilian R, Matschinger H, Loeffler W, Roick C, Angermeyer MC. A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment. J Ment Health Policy Econ. 2002;5:21–31.PubMed
29.
go back to reference Gregori D, Desideri A, Bigi R, Petrinco M, Cortigiani L, Zigon G, et al. Proper modeling strategies selection for the assessment of post-infarction costs. Int J Cardiol. 2008;129:53–8.PubMedCrossRef Gregori D, Desideri A, Bigi R, Petrinco M, Cortigiani L, Zigon G, et al. Proper modeling strategies selection for the assessment of post-infarction costs. Int J Cardiol. 2008;129:53–8.PubMedCrossRef
30.
go back to reference Griswold M, Parmigiani G, Potosky A, Lipscomb J. Analyzing health care costs: a comparison of statistical methods motivated by Maedicare colorectal cancer charges. Biostatistics. 2004;1:1–23. Griswold M, Parmigiani G, Potosky A, Lipscomb J. Analyzing health care costs: a comparison of statistical methods motivated by Maedicare colorectal cancer charges. Biostatistics. 2004;1:1–23.
31.
go back to reference Dudley RA, Harrell Jr FE, Smith LR, Mark DB, Califf RM, Pryor DB, et al. Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgery. J Clin Epidemiol. 1993;46:261–71.PubMedCrossRef Dudley RA, Harrell Jr FE, Smith LR, Mark DB, Califf RM, Pryor DB, et al. Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgery. J Clin Epidemiol. 1993;46:261–71.PubMedCrossRef
32.
go back to reference Lipscomb J, Ancukiewicz M, Parmigiani G, Hasselblad V, Samsa G, Matchar DB. Predicting the cost of illness: a comparison of alternative models applied to stroke. Med Decis Making. 1998;18:S39–56.PubMedCrossRef Lipscomb J, Ancukiewicz M, Parmigiani G, Hasselblad V, Samsa G, Matchar DB. Predicting the cost of illness: a comparison of alternative models applied to stroke. Med Decis Making. 1998;18:S39–56.PubMedCrossRef
Metadata
Title
Is the choice of the statistical model relevant in the cost estimation of patients with chronic diseases? An empirical approach by the Piedmont Diabetes Registry
Authors
Eva Pagano
Alessio Petrelli
Roberta Picariello
Franco Merletti
Roberto Gnavi
Graziella Bruno
Publication date
01-06-2015
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2015
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-015-1241-1

Other articles of this Issue 1/2015

BMC Health Services Research 1/2015 Go to the issue